|1.||Myszkowski, Krzysztof: 2 articles (05/2014 - 12/2013)|
|2.||Amarowicz, Ryszard: 2 articles (05/2014 - 12/2013)|
|3.||Murias, Marek: 2 articles (05/2014 - 12/2013)|
|4.||Jodynis-Liebert, Jadwiga: 2 articles (05/2014 - 12/2013)|
|5.||Wierzchowski, Marcin: 2 articles (05/2014 - 12/2013)|
|6.||Piotrowska, Hanna: 2 articles (05/2014 - 12/2013)|
|7.||Crooks, Peter A: 1 article (07/2015)|
|8.||Penthala, Narsimha Reddy: 1 article (07/2015)|
|9.||Thakkar, Shraddha: 1 article (07/2015)|
|10.||Abraszek, Joanna: 1 article (05/2014)|
07/15/2015 - "Interestingly, trans-3,4- and trans-3,5-dimethoxystyryl DMU-212 analogs 9, 10, 12 and 15 exhibited significantly less growth inhibition than their 3,4,5-trimethoxystyryl counterparts, suggesting that the trans-3,4,5-trimethoxystyryl moiety is an essential structural element for the potent anti-cancer activity of these heterocyclic DMU-212 analogs. "
07/15/2015 - "Heteroaromatic analogs of DMU-212 (8-15) have been synthesized and evaluated for their anti-cancer activity against a panel of 60 human cancer cell lines. "
05/01/2014 - "At day 14 of the experiment, tumor burden in mice treated with DMU-212 was significantly lower, as compared to untreated controls. "
05/01/2014 - "After seven days of the treatment with DMU-212 (50mg/kg b.w), tumor growth appeared to be suppressed in the animals treated with the compound tested. "
12/01/2013 - "The cytotoxic activity of DMU-212 has been shown to vary in cell lines derived from the same type of cancer, i.e. "
|2.||Ovarian Neoplasms (Ovarian Cancer)
05/01/2014 - "Our findings suggest that DMU-212 might be considered as a potential anticancer agent used in ovarian cancer therapy. "
05/01/2014 - "To evaluate in vitro metabolic properties of cells that were to be injected into SCID mice, uptake and decline of DMU-212 in A-2780 ovarian cancer cell line was investigated. "
05/01/2014 - "However, recently published data indicated the ability of DMU-212 to evoke apoptosis in both mitochondria- and receptor-mediated manner in two ovarian cancer cell lines, namely A-2780 and SKOV-3, which showed varied sensitivity to the compound tested. "
05/01/2014 - "In view of the great anticancer potential of DMU-212 against A-2780 cell line, the aim of the current study was to assess antiproliferative activity of DMU-212 in xenograft model of ovarian cancer. "
05/01/2014 - "DMU-212 inhibits tumor growth in xenograft model of human ovarian cancer."
|3.||Colonic Neoplasms (Colon Cancer)
12/01/2013 - "This study aims to elucidate the mechanism of antitumor effects of DMU-212 in two human colon cancer cell lines, DLD-1 and LOVO. "
12/01/2013 - "However, the molecular mechanism of DMU-212 cytotoxicity has not been clarified in colon cancer cells. "
12/01/2013 - "Different susceptibility of colon cancer DLD-1 and LOVO cell lines to apoptosis induced by DMU-212, a synthetic resveratrol analogue."
|4.||Breast Neoplasms (Breast Cancer)
05/01/2014 - "DMU-212 has been shown to evoke a mitochondrial apoptotic pathway in transformed fibroblasts and breast cancer. "
12/01/2008 - "The effects of DMU-212 and resveratrol on cell viability, cell cycle, Stat3 activation, and microtubule dynamic were investigated and compared using MTT assay, cell cycle analysis, Western blot, tubulin polymerization assay, respectively, in MDA-MB-435 and MCF-7 human breast cancer cells. "
06/10/2005 - "We tested the hypothesis that DMU-212 is also a more potent inhibitor of adenoma development in the Apc(Min+) mouse, a model of human intestinal carcinogenesis. "
06/10/2005 - "The results suggest that alteration of the resveratrol molecule to generate DMU-212 does not abrogate its ability to decrease adenoma number in Apc(Min+) mice or to interfere with PGE-2 generation in cells."
06/10/2005 - "Resveratrol and DMU-212 decreased adenoma load by 27% and 24%, respectively, compared to untreated controls. "
|3.||combretastatin A-4 (combretastatin A4)
|1.||Heterologous Transplantation (Xenotransplantation)